NEW YORK (GenomeWeb News) – Exact Sciences said today that it is undertaking a number of cost-reduction efforts, including laying off eight employees and suspending validation studies of its Version 2 stool-based technology for colorectal cancer screening, in an effort to conserve cash while “pursuing a strategic alternative for the business.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.